Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...

Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Rise in prevalence of ulcerative colitis and Crohn's disease, growing awareness of the disease across the world, drives the growth of the market David Correa Allied Market Research + 1 800-792-5285 ...

A NEW method for detecting bowel cancer is more than 90 per cent accurate at predicting which higher risk people will develop ...

The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...

Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in inflammatory bowel disease (IBD), Mount Sinai researchers have shown in a ...

Michael Osso leads the Crohn's & Colitis Foundation as president and CEO. The Foundation, the world's largest public nonprofit dedicated to inflammatory bowel disease (IBD), aims to find cures and ...

Lilly has also submitted marketing applications for Mirikizumab-mrkz in Crohn’s disease around the globe, including in the ...